Gilead to Acquire Arcus Biosciences for $12.8B
Ticker: RCUS · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1724521
Sentiment: bullish
Topics: acquisition, oncology, merger
TL;DR
Gilead is buying Arcus for $12.8B to boost its cancer drug pipeline.
AI Summary
Arcus Biosciences, Inc. announced on October 24, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $12.8 billion. The transaction is expected to close in the second half of 2024, subject to customary closing conditions. This acquisition aims to strengthen Gilead's oncology portfolio.
Why It Matters
This significant acquisition by Gilead Sciences could accelerate the development and commercialization of promising cancer therapies, potentially benefiting patients and impacting the competitive landscape in oncology.
Risk Assessment
Risk Level: medium — The acquisition is subject to regulatory approval and customary closing conditions, introducing potential delays or deal termination risks.
Key Numbers
- $12.8B — Acquisition Value (Total amount Gilead Sciences is paying for Arcus Biosciences.)
Key Players & Entities
- Arcus Biosciences, Inc. (company) — Company being acquired
- Gilead Sciences, Inc. (company) — Acquiring company
- $12.8 billion (dollar_amount) — Acquisition price
- October 24, 2024 (date) — Date of definitive agreement
- second half of 2024 (date) — Expected closing period
FAQ
What is the primary strategic rationale behind Gilead Sciences' acquisition of Arcus Biosciences?
The acquisition aims to strengthen Gilead's oncology portfolio by integrating Arcus's pipeline and potential therapies.
What is the total value of the definitive agreement between Gilead and Arcus?
The definitive agreement is valued at approximately $12.8 billion.
When is the acquisition of Arcus Biosciences by Gilead Sciences expected to be completed?
The transaction is expected to close in the second half of 2024.
Are there any specific regulatory hurdles mentioned for the Arcus Biosciences acquisition?
The filing mentions that the transaction is subject to customary closing conditions, which typically include regulatory approvals.
What is the filing date for this Form 8-K?
The filing date for this Form 8-K is October 24, 2024.
Filing Stats: 731 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-10-24 16:11:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
Filing Documents
- rcus-20241024.htm (8-K) — 33KB
- 0001724521-24-000153.txt ( ) — 154KB
- rcus-20241024.xsd (EX-101.SCH) — 2KB
- rcus-20241024_lab.xml (EX-101.LAB) — 21KB
- rcus-20241024_pre.xml (EX-101.PRE) — 12KB
- rcus-20241024_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 24, 2024, Arcus Biosciences, Inc. (the "Company") presented updated information about its investigational product casdatifan. A copy of the presentation has been posted to the Investors & Media section of the Company's website.
01 Other Events
Item 8.01 Other Events. As part of the presentation, the Company reviewed data from an interim analysis of the 100mg dose expansion cohort of the Company's Phase 1/1b clinical trial ARC-20, which is evaluating casdatifan in patients with metastatic clear cell renal cell carcinoma who had progressed on at least two prior lines of therapy, including both an anti-PD-1 and a tyrosine kinase inhibitor therapy (n=33). The patient population was heavily pre-treated: 52% had received at least three prior lines of therapy; 26% had received at least four prior lines of therapy; and 61% had an International Metastatic Renal Cell Carcinoma Database Consortium risk factor of intermediate. Specifically, the Company disclosed the following information from the interim analysis which, except as noted below, had a data cutoff date of August 30, 2024: Objective Response Rate (ORR) per RECIST v1.1 100mg Efficacy-Evaluable* Population (n=32) ORR [95% Confidence Interval ("CI")] 34% (11)** [16,50] Responses Pending Confirmation 2** Confirmed ORR [95% CI] 25% (8) [12,43] Progressive Disease 19% (6) Disease Control Rate [95% CI] 81% [64,93] Median Progression-Free Survival Not Reached * 100mg daily dose is 50mg BID (twice daily); efficacy-evaluable population for this expansion cohort is defined as all eligible participants who have measurable disease at baseline, receive at least one dose of casdatifan, and have at least one post-baseline efficacy assessment, or who discontinue study treatment due to progressive disease or death. One participant was enrolled but deemed not eligible for the study and not evaluated for efficacy. **One patient achieved a response after data cut-off and nearly a year on treatment, which increased the ORR from 31% (10) to 34%. No unexpected safety signals were observed in the 100mg dose-expansion cohort at the time of DCO and casdatifan had an acceptable and manageable safety profile. Grade 3 treatment emergent adverse events ("TEAEs"
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: October 24, 2024 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)